Literature DB >> 16488021

The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum.

Hagop S Akiskal1, Franco Benazzi.   

Abstract

BACKGROUND: Presently it is a hotly debated issue whether unipolar and bipolar disorders are categorically distinct or lie on a spectrum. We used the ongoing Ravenna-San Diego Collaboration database to examine this question with respect to major depressive disorder (MDD) and bipolar II (BP-II).
METHODS: The study population in FB's Italian private practice setting comprised consecutive 650 outpatients presenting with major depressive episode (MDE) and ascertained by a modified version of the Structured Clinical Interview for DSM-IV. Differential assignment of patients into MDD versus BP-II was made on the basis of discrete hypomanic episodes outside the timeframe of an MDE. In addition, hypomanic signs and symptoms during MDE (intra-MDE hypomania) were systematically assessed and graded by the Hypomania Interview Guide (HIG). The frequency distributions of the HIG total scores in each of the MDD, BP-II and the combined entire sample were plotted using the kernel density estimate. Finally, bipolar family history (BFH) was investigated by structured interview (the Family History Screen).
RESULTS: There were 261 MDD and 389 BP-II. As in the previous smaller samples, categorically defined BP-II compared with MDD had significantly earlier age at onset, higher rates of familial bipolarity (mostly BP-II), history of MDE recurrences (>or=5), and atypical features. However, examining hypomania scores dimensionally, whether we examined the MDD, BP-II, or the combined sample, kernel density estimate distribution of these scores had a normal-like shape (i.e., no bimodality). Also, in the combined sample of MDE, we found a dose-response relationship between BFH loading and intra-MDE hypomania measured by HIG scores. LIMITATIONS: Although the interviewer (FB) could not be blind to the diagnostic status of his private patients, the systematic rigorous interview process in a very large clinical population minimized any unintended biases.
CONCLUSIONS: Unlike previous studies that have examined the number of DSM-IV hypomanic signs and symptoms both outside and during MDE, the present analyses relied on the more precise hypomania scores as measured by the HIG. The finding of a dose-response relationship between BFH and HIG scores in the sample at large strongly suggests a continuity between BP-II and MDD. Our data indicate that even in those clinically depressed patients without past hypomanic episodes (so-called "unipolar" MDD), such scores are normally rather than bimodally distributed during MDE. Moreover, the absence of a 'zone of rarity' in the distribution of hypomanic scores in the combined total, MDD and BP-II MDE samples, indicates that MDD and BP-II exist on a dimensional spectrum. From a nosologic perspective, our data are contrary to what one would expect from a categorical unipolar-bipolar distinction. In practical terms, intra-MDE hypomania and BFH, especially in recurrent MDD, represent strong indicators of bipolarity.

Entities:  

Mesh:

Year:  2006        PMID: 16488021     DOI: 10.1016/j.jad.2005.12.035

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  17 in total

Review 1.  The A, B, C's of factitious disorder: a response to Turner.

Authors:  James C Hamilton; Marc D Feldman; Jeffrey W Janata
Journal:  Medscape J Med       Date:  2009-01-27

2.  The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression.

Authors:  Adriano Zanello; Laurent Berthoud; Joseph Ventura; Marco C G Merlo
Journal:  Psychiatry Res       Date:  2013-07-26       Impact factor: 3.222

3.  Current psychopathological issues in psychosis: towards a phenome-wide scanning approach.

Authors:  Manuel J Cuesta; Victor Peralta
Journal:  Schizophr Bull       Date:  2008-05-14       Impact factor: 9.306

4.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

Review 5.  The significance of mixed states in depression and mania.

Authors:  Giulio Perugi; Giuseppe Quaranta; Liliana Dell'Osso
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

Review 6.  [Core symptoms of depression. Effectiveness of antidepressant therapy].

Authors:  J Damm; D Eser; C Schüle; H-J Möller; R Rupprecht; T C Baghai
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

7.  Social phobia and number of social fears, and their association with comorbidity, health-related quality of life and help seeking: a population-based study.

Authors:  C Acarturk; Ron de Graaf; A van Straten; M Ten Have; P Cuijpers
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-01-24       Impact factor: 4.328

8.  The structure of lifetime manic-hypomanic spectrum.

Authors:  G B Cassano; M Mula; P Rucci; M Miniati; E Frank; D J Kupfer; A Oppo; S Calugi; L Maggi; R Gibbons; A Fagiolini
Journal:  J Affect Disord       Date:  2008-06-09       Impact factor: 4.839

9.  Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

Authors:  Antonella Benvenuti; Paola Rucci; Simona Calugi; Giovanni B Cassano; Mario Miniati; Ellen Frank
Journal:  Int Clin Psychopharmacol       Date:  2010-03       Impact factor: 1.659

10.  Epidemiology of mental disorders in children and adolescents.

Authors:  Kathleen Ries Merikangas; Erin F Nakamura; Ronald C Kessler
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.